Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGENNASDAQ:CGENNASDAQ:DTILNASDAQ:PDLINASDAQ:VYGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$5.51+13.8%$4.06$1.38▼$18.74$132.70M1.51681,754 shs1.12 million shsCGENCompugen$1.74+0.6%$1.54$1.13▼$2.66$154.38M2.57369,385 shs146,002 shsDTILPrecision BioSciences$4.26+3.1%$4.94$3.61▼$11.09$45.79M1.43223,876 shs170,521 shsPDLIPDL BioPharma$2.47$2.47$2.09▼$3.86N/AN/AN/AN/AVYGRVoyager Therapeutics$3.20+2.6%$3.23$2.65▼$9.55$172.65M0.85481,318 shs655,825 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus+13.84%+11.76%+33.41%+244.38%-61.41%CGENCompugen+0.58%+2.96%+16.00%+23.40%+2.96%DTILPrecision BioSciences+3.15%+0.47%-15.48%-9.55%-54.73%PDLIPDL BioPharma0.00%0.00%0.00%0.00%0.00%VYGRVoyager Therapeutics+2.56%+8.84%-2.74%+2.89%-57.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGENAgenus4.3048 of 5 stars3.24.00.04.62.21.70.6CGENCompugen2.3041 of 5 stars3.53.00.00.03.80.00.0DTILPrecision BioSciences4.5876 of 5 stars3.53.00.04.62.91.71.3PDLIPDL BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AVYGRVoyager Therapeutics3.9723 of 5 stars3.61.00.04.62.70.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGENAgenus 2.33Hold$14.00154.08% UpsideCGENCompugen 3.00Buy$4.00129.89% UpsideDTILPrecision BioSciences 3.00Buy$47.001,003.29% UpsidePDLIPDL BioPharma 0.00N/AN/AN/AVYGRVoyager Therapeutics 3.13Buy$13.39318.44% UpsideCurrent Analyst Ratings BreakdownLatest VYGR, DTIL, CGEN, PDLI, and AGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2025AGENAgenusRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$4.00 ➝ $6.006/4/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$25.005/21/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.005/13/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/13/2025AGENAgenusRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$3.00 ➝ $4.004/30/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral4/21/2025AGENAgenusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/8/2025VYGRVoyager TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGENAgenus$103.46M1.46N/AN/A($13.06) per share-0.42CGENCompugen$27.86M5.57N/AN/A$0.62 per share2.81DTILPrecision BioSciences$68.70M0.69N/AN/A$6.87 per share0.62PDLIPDL BioPharmaN/AN/AN/AN/AN/AN/AVYGRVoyager Therapeutics$80M2.21N/AN/A$5.49 per share0.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGENAgenus-$227.21M-$8.67N/AN/AN/A-196.12%N/A-82.33%8/6/2025 (Estimated)CGENCompugen-$14.23M-$0.16N/AN/AN/A-51.27%-24.51%-12.19%8/5/2025 (Estimated)DTILPrecision BioSciences$7.17M-$2.01N/AN/AN/A-42.99%-69.26%-29.30%7/30/2025 (Estimated)PDLIPDL BioPharmaN/A$0.1913.00∞N/AN/AN/AN/AN/AVYGRVoyager Therapeutics-$65M-$1.46N/AN/AN/A-126.49%-27.36%-21.06%8/5/2025 (Estimated)Latest VYGR, DTIL, CGEN, PDLI, and AGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025CGENCompugen-$0.06-$0.08-$0.02-$0.08$3.70 million$2.28 million5/15/2025Q1 2025DTILPrecision BioSciences-$0.43-$2.21-$1.78-$2.21$5.00 million$0.03 million5/12/2025Q1 2025AGENAgenus-$1.61-$1.03+$0.58-$1.03$26.38 million$24.07 million5/6/2025Q1 2025VYGRVoyager Therapeutics-$0.35-$0.53-$0.18-$0.53$13.55 million$6.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGENAgenusN/AN/AN/AN/AN/ACGENCompugenN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/APDLIPDL BioPharmaN/AN/AN/AN/AN/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGENAgenusN/A0.110.11CGENCompugenN/A5.095.09DTILPrecision BioSciences0.456.626.62PDLIPDL BioPharmaN/AN/AN/AVYGRVoyager TherapeuticsN/A6.106.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGENAgenus61.46%CGENCompugen12.22%DTILPrecision BioSciences37.99%PDLIPDL BioPharmaN/AVYGRVoyager Therapeutics48.03%Insider OwnershipCompanyInsider OwnershipAGENAgenus5.50%CGENCompugen9.50%DTILPrecision BioSciences4.50%PDLIPDL BioPharma2.20%VYGRVoyager Therapeutics6.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGENAgenus44027.42 million25.91 millionOptionableCGENCompugen7089.24 million80.76 millionOptionableDTILPrecision BioSciences20011.09 million10.59 millionNo DataPDLIPDL BioPharma109N/AN/AOptionableVYGRVoyager Therapeutics10055.34 million51.80 millionOptionableVYGR, DTIL, CGEN, PDLI, and AGEN HeadlinesRecent News About These CompaniesVYGR Voyager Therapeutics, Inc. - Seeking AlphaJune 25, 2025 | seekingalpha.comMajor Security Breach at RAF Brize Norton Sees Protesters Spray Voyager Aircraft With PaintJune 20, 2025 | theaviationist.comTProtesters Vandalize RAF Voyager Tankers In Palestine ProtestJune 20, 2025 | aviationweek.comAVoyager Technologies Soars with IPO SuccessJune 14, 2025 | devdiscourse.comDSpace Tech Ventures Surge: Voyager's IPO Success and Starlink's Swiss ExpansionJune 12, 2025 | devdiscourse.comDVoyager Technologies Rises in Debut, Signaling Improving IPO MarketJune 12, 2025 | msn.comVoyager soars 82% on first day of trading as defense tech boomsJune 12, 2025 | msn.comInvestor demand for Voyager’s stock keeps growing, despite a mixed history for space-tech IPOsJune 11, 2025 | msn.comVoyager Technologies' Shares More Than Double in NYSE DebutJune 11, 2025 | marketwatch.comVoyager Technologies Shares Soar In Market DebutJune 11, 2025 | news.crunchbase.comNSpace tech firm Voyager valued at $3.8 billion as shares surge in NYSE debutJune 11, 2025 | aol.comAVoyager raises $383 million from upsized IPOJune 11, 2025 | spacenews.comSSpace and defense tech firm Voyager raises $382.8 million in IPOJune 11, 2025 | fastcompany.comFVoyager Technologies Valued at $3.8 Billion in Stellar NYSE DebutJune 11, 2025 | msn.comVoyager Technologies’ IPO shows investors are still hot on space stocks, despite a mixed historyJune 11, 2025 | marketwatch.comVoyager Announces Pricing of Initial Public OfferingJune 10, 2025 | bakersfield.comBBrokers Issue Forecasts for VYGR FY2026 EarningsJune 10, 2025 | marketbeat.comVoyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid ConferenceJune 10, 2025 | globenewswire.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Recommendation of "Buy" from AnalystsJune 10, 2025 | marketbeat.comVoyager Therapeutics: Navigating AAV Headwinds And A Long Road For VY7523 (Downgrade)June 7, 2025 | seekingalpha.comVoyager Technologies, Inc. Announces Launch of Initial Public OfferingJune 3, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVYGR, DTIL, CGEN, PDLI, and AGEN Company DescriptionsAgenus NASDAQ:AGEN$5.51 +0.67 (+13.84%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$5.50 -0.01 (-0.20%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Compugen NASDAQ:CGEN$1.74 +0.01 (+0.58%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$1.72 -0.01 (-0.86%) As of 07/2/2025 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Precision BioSciences NASDAQ:DTIL$4.26 +0.13 (+3.15%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$4.21 -0.05 (-1.17%) As of 07/2/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.PDL BioPharma NASDAQ:PDLIPDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.Voyager Therapeutics NASDAQ:VYGR$3.20 +0.08 (+2.56%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$3.22 +0.02 (+0.75%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Jefferies Raises Broadcom Price Target to $315: 19% Upside Ahead Dan Ives’ Bold $5 Trillion Forecast for Microsoft Stock 3 Utility Stocks That Combine Income and Stability 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.